Brainomix announced the discovery of an automated imaging biomarker that can predict lung function decline and survival of patients with idiopathic pulmonary fibrosis (IPF), as published in their press release.

The quantification of this novel imaging biomarker through the latest version of Brainomix’s e-ILD software may allow a 2-fold increase in the ability to predict transplant-free survival when compared to the conventional forced vital capacity endpoint.

“We are pleased to see these encouraging data and developments from Brainomix as they highlight the important value of our consortium in enabling the development of novel solutions to combat pulmonary fibrosis,” Elizabeth Estes, executive director of the Open Source Imaging Consortium (OSIC) said.

Continue Reading

Read more about IPF prognosis

The combination of automated e-ILD imaging biomarkers with respiratory physiology is expected to improve the identification of patients with IPF who are at most risk of disease progression, as well as the assessment of therapeutic response in clinical trials.

“Composite endpoints including automated e-ILD image analysis offer a better surrogate of transplant-free survival than traditional clinico-physiological markers alone which are conventionally used in this [clinical trial] setting,” the company said.

Artificial Intelligence Aids in Prognosis of Idiopathic Pulmonary Fibrosis

Brainomix analyzed high-resolution computerized tomography (HRCT) scans from patients with IPF using artificial intelligence (AI), a machine learning approach, and identified several AI-powered imaging biomarkers. Among them, a proprietary biomarker was able to quantify the extent of the lung affected by reticulo-vascular abnormalities.

To develop the AI-based machine learning approach, Brainomix used a large set of anonymized HRCT scans and clinical data from the OSIC data repository. OSIC is a not-for-profit, collaborative effort that brings together academia, industry, and patient advocacy groups to accelerate the knowledge on fighting against IPF, interstitial lung diseases, and other respiratory diseases (eg, emphysematous conditions).


Brainomix announces the development of a proprietary AI-trained predictive biomarker for idiopathic pulmonary fibrosis (IPF). News release. Brainomix; February 8, 2022.